Callisto Pharmaceuticals, Incorporation - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Callisto Pharmaceuticals, Incorporation. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Callisto Pharmaceuticals, Incorporation. The Group's principal activity is developing drugs to treat relapsed acute leukemia, multiple myeloma, and advanced carcinoid cancer patients. Its drug candidate, L-Annamycin, a drug from the anthracycline family completed an initial Phase I/IIa clinical trial. Its second drug candidate, Atiprimod, is an orally administered drug with antiproliferative and antiangiogenic activity completed a Phase I/IIa clinical trial. The company is in a development stage and its operations are located in the United States.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report